Pyrogen Testing Market to hit USD 2.8 billion by 2032, says Global Market Insights Inc.
Global Market Insights Inc.
Global Market Insights Inc.

Pyrogen testing industry is projected to witness a CAGR of 9.1% during the period 2024-2032. This growth can be attributed to the growing investment in R&D.

Selbyville, Delaware, Nov. 04, 2024 (GLOBE NEWSWIRE) --

Pyrogen Testing Market size is estimated to be valued at USD 2.8 billion in revenue by 2032. The industry growth is driven by the expanding pharmaceutical and biotechnology industries. As the rate of drug development and biologics manufacturing increases globally, there is a greater demand for pyrogen testing to ensure the safety of products like vaccines, injectable drugs, and medical devices.

Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/8867

Regulatory bodies, such as the FDA and EMA, require stringent testing to detect pyrogens, which are fever-causing substances that can trigger harmful reactions in patients. The rise in biologics, monoclonal antibodies, and cell-based therapies has also intensified the need for accurate and reliable pyrogen testing methods.

Rapid advancements in testing technologies, such as recombinant factor C (rFC) assays and vitro methods, have further accelerated the pyrogen testing market development. These modern testing methods provide more efficient, ethical, and cost-effective alternatives to traditional animal-based tests like the rabbit pyrogen test. The increasing focus on animal welfare, along with the push for more sustainable and faster testing processes, has encouraged the adoption of these innovative techniques. The growing emphasis on quality control and safety in pharmaceutical production, particularly in emerging markets.

Rising adoption of in-vitro pyrogen tests

In terms of test type, the pyrogen testing market from the in vitro pyrogen test segment is slated to record a significant CAGR between 2024 and 2032 due to its ethical, efficient, and cost-effective advantages over traditional animal-based methods. In vitro tests, such as the monocyte activation test (MAT) offer more precise and reliable detection of pyrogens without the need for live animals, aligning with the increasing focus on animal welfare and regulatory requirements. These tests further provide faster results and can be easily standardized, making them more appealing for pharmaceutical and biotechnology companies aiming to streamline their safety testing processes.

Strong demand in medical device companies

With respect to end use, the pyrogen testing market from the medical device companies segment is poised to grow at a substantial rate during 2024- 2032 backed by the critical need to ensure the safety and sterility of devices that come into direct contact with the human body. As the use of implants, catheters, and other medical devices increases, regulatory requirements for pyrogen testing have become more stringent. Pyrogen testing also helps prevent harmful reactions caused by endotoxins or other fever-inducing contaminants.